<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04227249</url>
  </required_header>
  <id_info>
    <org_study_id>KGOG 3021</org_study_id>
    <nct_id>NCT04227249</nct_id>
  </id_info>
  <brief_title>3 Year Recurrence Free Survival in Ultra-low-risk Endometrial Cancer</brief_title>
  <acronym>TREE PRO</acronym>
  <official_title>Three-year Recurrence Free Survival in Patients With Ultra-low-risk Endometrial Cancer Who do Not Undergo Lymph Node dissEction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To verify the safety of omission of lymph node dissection in ultra-low-risk endometrial
      cancer (KGOG criteria), we examine the survival of women with ultra-low-risk endometrial
      cancer who do not undergo lymph node dissection
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">March 2027</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>3 year recurrence free survival</measure>
    <time_frame>3 year since surgery</time_frame>
    <description>3 year recurrence free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>5 year recurrence free survival</measure>
    <time_frame>5 year since surgery</time_frame>
    <description>5 year recurrence free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5 year overall survival</measure>
    <time_frame>5 year since surgery</time_frame>
    <description>5 year overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>surgery time</measure>
    <time_frame>surgery visit</time_frame>
    <description>from surgery start to end</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of Functional Assessment of Cancer Therapy - General (FACT G) score from baseline</measure>
    <time_frame>baseline - 1week - 5week - 3month - 6month</time_frame>
    <description>functional assessment of cancer therapy - general</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of Gynecologic Cancer Lymphedema Questionnaire - Korean (GCLQ-K) score from baseline</measure>
    <time_frame>baseline - 5week - 6month - 12month - 18month - 24month - 36month - 48month - 60month</time_frame>
    <description>gynecologic cancer lymphedema questionnaire - Korean</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of Female Sexual Function Index (FSFI) score from baseline</measure>
    <time_frame>baseline - 6month - 12month - 24month - 36month - 48month - 60month</time_frame>
    <description>female sexual function index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stay</measure>
    <time_frame>surgery visit</time_frame>
    <description>from admission to discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transfusion</measure>
    <time_frame>surgery visit</time_frame>
    <description>amount of transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemoglobin decline</measure>
    <time_frame>surgery visit</time_frame>
    <description>change of hemoglobin level from baseline to postoperative lowest level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>surgery complication</measure>
    <time_frame>surgery visit</time_frame>
    <description>any surgery complications observed</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">153</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <description>women who do not undergo lymph node dissection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>no lymph node dissection</intervention_name>
    <description>do not undergo lymph node dissection</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        endometrial cancer with ultra-low risk for lymph node metastasis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  endometrioid type

          -  anticipated surgery omitting lymph node dissection for endometrial cancer

          -  pelvis MRI, CA125 - satisfying KGOG criteria

          -  no distant metastasis

          -  age 19 or more

        Exclusion Criteria:

          -  other cancer within 5 yr

          -  previous hysterectomy

          -  previous therapy for endometrial cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>kidong kim, md</last_name>
    <phone>82 31 787 7262</phone>
    <email>kidong.kim.md@gmail.com</email>
  </overall_contact>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 2, 2020</study_first_submitted>
  <study_first_submitted_qc>January 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>January 12, 2020</last_update_submitted>
  <last_update_submitted_qc>January 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

